Solid Dispersion Amorphous Stabilization via Hypromellose Matrix
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Poorly soluble compounds used in treating hyperuricemia, such as those disclosed in Patent Literature 1, face challenges with in vivo absorbability and storage stability when formulated as solid dispersions, as they can revert from an amorphous form to a crystalline state over time, affecting solubility consistency.
Innovation Solution
A solid dispersion containing a compound with xanthine oxidase inhibitory activity, represented by General Formula (I), is combined with a hypromellose derivative like hypromellose acetate succinate, forming a uniform mixture with a weight ratio between 1:0.1 to 1:25, and produced using methods like spray drying to maintain an amorphous form and enhance stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If a poorly soluble compound is formulated as a solid dispersion to improve in vivo absorbability, then solubility is improved, but the compound may change from amorphous form to crystal during long-term storage, affecting solubility consistency
Solution Approach 1:
The patent uses hypromellose derivative as an intermediary substance to stabilize the amorphous compound. The polymer acts as a matrix that prevents molecular reorganization and crystallization, maintaining the amorphous state and consistent solubility properties during long-term storage
Solution Approach 2:
The invention creates a composite material system combining the poorly soluble compound with hypromellose derivative in a specific weight ratio (1:0.1 to 1:25). This composite structure provides both the solubility enhancement of amorphous dispersion and the storage stability of the polymer matrix
2Stability of the object's composition
If a compound is micronized to improve in vivo absorbability, then solubility is improved, but manufacturing complexity increases
Solution Approach 1:
The patent changes the physical state parameter of the compound from crystalline to amorphous through solid dispersion formation. This parameter change improves solubility without requiring micronization, thereby simplifying the manufacturing process while achieving the desired solubility enhancement
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The resulting solid dispersion exhibits improved in vivo absorbability and storage stability, maintaining solubility and effectiveness over time, making it a therapeutic agent for hyperuricemia and related conditions.
Implementation Method 1
it is necessary to form the poorly soluble compound into an amorphous form. However, since such a poorly soluble compound may change from an amorphous form to a crystal during long-term storage depending on the combination of a poorly soluble compound and a polymer
Implementation Method 2
produced using methods like spray drying to maintain an amorphous form and enhance stability
Data Source
Figure 1(a)~1(d)
Figure 2(a)~2(d)
Figure 3(a)~3(d)
AI summary
The present invention relates to a solid dispersion containing a compound represented by General Formula (I): wherein R1 is an unsubstituted phenyl group or a phenyl group substituted with a substituent; the substituent is an alkyl group having 1 to 8 carbon atoms, an alkyl group having 1 to 8 carbon atoms substituted with a halogen atom, an alkoxy group having 1 to 8 carbon atoms, an alkoxycarbonyl group having 2 to 8 carbon atoms, a formyl group, a carboxyl group, a halogen atom, a phenyl group or a phenoxy group; R2 is a cyano group or a nitro group; R3 is a hydroxyl group; X is an oxygen atom or -S(O)n-; n is an integer of 0 to 2; Y is an oxygen atom or a sulfur atom, or a pharmaceutically acceptable salt thereof and a hypromellose derivative.